期刊文献+

Genetically modified mouse models for the study of nonalcoholic fatty liver disease 被引量:7

Genetically modified mouse models for the study of nonalcoholic fatty liver disease
下载PDF
导出
摘要 Nonalcoholic fatty liver disease(NAFLD) is associated with obesity,insulin resistance,and type 2 diabetes.NAFLD represents a large spectrum of diseases ranging from(1) fatty liver(hepatic steatosis);(2) steatosis with inflammation and necrosis;to(3) cirrhosis.The animal models to study NAFLD/nonalcoholic steatohepatitis(NASH) are extremely useful,as there are still many events to be elucidated in the pathology of NASH.The study of the established animal models has provided many clues in the pathogenesis of steatosis and steatohepatitis,but these remain incompletely understood.The different mouse models can be classified in two large groups.The first one includes genetically modified(transgenic or knockout) mice that spontaneously develop liver disease,and the second one includes mice that acquire the disease after dietary or pharmacological manipulation.Although the molecular mechanism leading to the development of hepatic steatosis in the pathogenesis of NAFLD is complex,genetically modified animal models may be a key for the treatment of NAFLD.Ideal animal models for NASH should closely resemble the pathological characteristics observed in humans.To date,no single animal model has encompassed the full spectrum of human disease progression,but they can imitate particular characteristics of human disease.Therefore,it is important that the researchers choose the appropriate animal model.This review discusses various genetically modified animal models developed and used in research on NAFLD. Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and type 2 diabetes. NAFLD represents a large spectrum of diseases ranging from (1) fatty liver (hepatic steatosis); (2) steatosis with inflammation and necrosis; to (3) cirrhosis. The animal models to study NAFLD/nonalcoholic steatohepatitis (NASH) are extremely useful, as there are still many events to Be elucidated in the pathology of NASH. The study of the established animal models has provided many clues in the pathogenesis of steatosis and steatohepatitis, but these remain incompletely understood. The different mouse models can be classified in two large groups. The first one includes genetically modified (transgenic or knockout) mice that spontaneously develop liver disease, and the second one includes mice that acquire the disease after dietary or pharmacological manipulation. Although the molecular mechanism leading to the development of hepatic steatosis in the pathogenesis of NAFLD is complex, genetically modified animal models may be a key forthe treatment of NAFLD. Ideal animal models for NASH should closely resemble the pathological characteristics observed in humans. To date, no single animal model has encompassed the full spectrum of human disease progression, but they can imitate particular characteristics of human disease. Therefore, it is important that the researchers choose the appropriate animal model. This review discusses various genetically modified ani- mal models developed and used in research on NAFLD.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第11期1141-1153,共13页 世界胃肠病学杂志(英文版)
关键词 转基因小鼠模型 脂肪肝 酒精性 转基因动物模型 肝病 人类疾病 NASH 发病机制 Nonalcoholic fatty liver disease Steatosis Steatohepatitis Knockout Animal models
  • 相关文献

参考文献2

二级参考文献119

  • 1[1]Kleiner DE,Brunt EM,Van Natta M,Behling C,Contos MJ,Cummings OW,Ferrell LD,Liu YC,Torbenson MS,Unalp-Arida A,Yeh M,McCullough AJ,Sanyal AJ.Design and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology 2005;41:1313-1321
  • 2[2]Browning JD,Szczepaniak LS,Dobbins R,Nuremberg P,Horton JD,Cohen JC,Grundy SM,Hobbs HH.Prevalence of hepatic steatosis in an urban population in the United States:impact of ethnicity.Hepatology 2004;40:1387-1395
  • 3[3]Schwimmer JB,Deutsch R,Kahen T,Lavine JE,Stanley C,Behling C.Prevalence of fatty liver in children and adolescents.Pediatrics 2006;118:1388-1393
  • 4[4]Marchesini G,Bugianesi E,Forlani G,Cerrelli F,Lenzi M,Manini R,Natale S,Vanni E,Villanova N,Melchionda N,Rizzetto M.Nonalcoholic fatty liver,steatohepatitis,and the metabolic syndrome.Hepatology 2003;37:917-923
  • 5[5]Neuschwander-Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology 2003;37:1202-1219
  • 6[6]Angulo P.Nonalcoholic fatty liver disease.N Engl J Med 2002;346:1221-1231
  • 7[7]Adams LA,Lymp JF,St Sauver J,Sanderson SO,Lindor KD,Feldstein A,Angulo P.The natural history of nonalcoholic fatty liver disease:a population-based cohort study.Gastroenterology 2005;129:113-121
  • 8[8]Matteoni CA,Younossi ZM,Gramlich T,Boparai N,Liu YC,McCullough AJ.Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity.Gastroenterology 1999;116:1413-1419
  • 9[9]Caldwell SH,Oelsner DH,Iezzoni JC,Hespenheide EE,Battle EH,DriscoU CJ.Cryptogenic cirrhosis:clinical characterization and risk factors for underlying disease.Hepatology 1999;29:664-669
  • 10[10]Marrero JA,Fontana RJ,Su GL,Conjeevaram HS,Emick DM,Lok AS.NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.Hepatology 2002;36:1349-1354

共引文献44

同被引文献119

引证文献7

二级引证文献115

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部